Hickey Benjamin 4

What Happened Benjamin Hickey, President — RayzeBio organization at Bristol Myers Squibb (BMY), had 10,079 restricted stock units (RSUs) convert into 10,079 shares on February 1, 2026 (reported as derivative exercise/conversion). To satisfy tax withholding on the vesting, 3,810 of those shares were withheld and valued at $55.05 each, totaling $209,741. Net shares delivered to Hickey after withholding were 6,269 (10,079 converted minus 3,810 withheld). The conversion/exercise reported an exercise price of $0 (typical for RSU vesting).

Key Details

• Transaction date: February 1, 2026 (reported Feb 3, 2026).
• Reported transactions: M (conversion/exercise of derivative) — 10,079 RSUs converted to 10,079 shares; F (tax withholding) — 3,810 shares withheld at $55.05 totaling $209,741.
• Net shares received by insider: 6,269 shares (10,079 − 3,810).
• Footnotes: F1 — RSUs vest annually in three equal installments beginning Feb 1, 2025; F2 — shares were withheld to pay taxes on vesting; F3 — each RSU converts into one common share upon vesting.
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Form filed Feb 3, 2026 for a Feb 1, 2026 event; no late filing flag indicated.

Context This was a routine vesting/conversion of RSUs, not an open-market purchase or voluntary sale. The withholding of shares to cover taxes is a common cashless method of satisfying tax obligations on vested awards and does not necessarily indicate a change in insider sentiment. The M code reflects conversion/exercise of the derivative (RSU → common share); the F code reflects the disposition of shares for tax withholding.